Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.

Abstract excerpt

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and are now the preferred treatment for several tumor types. Though ICIs have shown remarkable efficacy in several cancer histologies, in many cases providing long-term disease control, not all patients will derive clinical benefit from such approaches. Given the lack of a reliable predictive biomarker for therapeutic responses to ICIs, we...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents, Immunological
• Share to Biomarkers, Tumor
• Share to Carcinoma, Non-Small-Cell Lung